ZymoGenetics

Founded in 1981, ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins. ZymoGenetics is publicly traded (NASDAQ: ZGEN) and headquartered in Seattle, Washington in the historic Seattle City Light Steam Plant building.

Our mission is to create novel protein drugs that will significantly help patients fight their diseases. We have contributed to the discovery or development of six recombinant protein products now marketed by other companies. Current programs target viral infection, cancer, inflammatory diseases and bleeding. Our first internally developed product, RECOTHROM® Thrombin, topical (Recombinant), was approved by the U.S. Food and Drug Administration (FDA) on January 17, 2008 for use as a topical hemostat to control moderate bleeding during surgical procedures and is now marketed in the United States. We have a promising pipeline of novel therapeutics, which we are developing on our own or in collaboration with partners.

For 2010, our planned milestones are:

1. PEG-Interferon lambda: Complete enrollment in the Phase 2a part of the study; present 4 week and 12 week results from Phase 2a; initiate Phase 2b part of the study
2. RECOTHROM: Continuing market penetration; reach net positive contribution to P&L
3. IL-21:  Begin Phase 2b randomized study in metastatic melanoma; present Phase 2a melanoma final results
4. IL-31 mAb: Complete manufacturing to support Phase 1; begin IND-enabling toxicology studies

ZymoGenetics is an emerging leader among biopharmaceutical companies.